



Published in final edited form as:

*P R Health Sci J.* 2015 June ; 34(2): 65–70.

## Recent Advances in Dengue: Relevance to Puerto Rico

David H. Noyd, BA<sup>\*</sup> and Tyler M. Sharp, PhD<sup>†</sup>

<sup>\*</sup>Oregon Health & Science University, Dengue Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR

<sup>†</sup>Dengue Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan, PR

### Abstract

Dengue represents an increasingly important public health challenge in Puerto Rico, with recent epidemics in 2007, 2010, and 2012–2013. Although recent advances in dengue vaccine development offer hope for primary prevention, the role of health professionals in the diagnosis and management of dengue patients is paramount. Case definitions for dengue, dengue with warning signs, and severe dengue provide a framework to guide clinical decision-making. Furthermore, the differentiation between dengue and other acute febrile illnesses, such as leptospirosis and chikungunya, is necessary for the appropriate diagnosis and management of cases. An understanding of dengue epidemiology and surveillance in Puerto Rico provides context for clinicians in epidemic and non-epidemic periods. This review aims to improve health professionals' ability to diagnose dengue, and as highlight the relevance of recent advances in dengue prevention and management in Puerto Rico.

### Keywords

Dengue; Epidemiology; Public Health

Dengue represents an increasingly important global health challenge, as recent estimates suggest that nearly 2.5 billion people worldwide are at risk for infection (1) and 390 million infections occurred in 2010 (2). The 4 dengue virus-types (DENV-1–4) that cause dengue are single-stranded, positive-sense RNA viruses of the family *Flaviviridae*. *Aedes aegypti* and *Ae. albopictus* mosquitoes are endemic throughout the tropics and subtropics and serve as the primary vector for DENV transmission. DENV infection can result in a range of outcomes, from asymptomatic infection, to self-limited acute febrile illness (AFI), to potentially fatal severe dengue (1).

In 2009, the World Health Organization (WHO) revised the clinical classification of dengue, reclassifying dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome

Address correspondence to: Tyler M. Sharp, PhD, Centers for Disease Control and Prevention - Dengue Branch, 1324 Calle Canada, San Juan, PR 00920. tsharp@cdc.gov.

The authors have no conflicts of interest to disclose.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or CDC.

(DSS) (3) as dengue, dengue with warning signs, and severe dengue (1). A major impetus for this change was the observation that many life-threatening dengue cases did not meet the definition of either DHF or DSS, and the identification of clinical signs and symptoms present in some dengue cases were positively associated with the development of more severe illness (4, 5). Dengue is characterized by fever, anorexia, rash, aches and pains, and leucopenia (1). Warning signs that signal development of severe dengue include abdominal pain, persistent vomiting, mucosal bleed, hepatomegaly greater than 2 centimeters, clinical fluid accumulation, lethargy or restlessness, and hemoconcentration concurrent with a rapid decrease in platelet count. Severe dengue is characterized by plasma leakage that may lead to shock, severe bleeding, severe organ impairment or any combination thereof.

In Puerto Rico, clinical suspicion of dengue should be followed by the collection of a serum specimen and completion of a Dengue Case Investigation Form (available at [www.cdc.gov/dengue/resources/dengueCaseReports/DCIF\\_English.pdf](http://www.cdc.gov/dengue/resources/dengueCaseReports/DCIF_English.pdf) or [www.cdc.gov/dengue/resources/dengueCaseReports/DCIF\\_Spanish.pdf](http://www.cdc.gov/dengue/resources/dengueCaseReports/DCIF_Spanish.pdf)) to enable case reporting and diagnostic testing by either reverse transcriptase-polymerase chain reaction (RT-PCR) to directly detect viral genome and/or IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) to detect anti-DENV immunoglobulin M (IgM) antibodies. Although primary DENV infection confers lifelong immunity to the infecting DENV type, subsequent infection with another DENV type confers a slight but statistically significant increased risk of developing more severe illness (6).

Currently, no vaccine or anti-viral drug is available to prevent or treat dengue, although several vaccine candidates are in clinical trials (7, 8). The mainstay for treatment of dengue is therefore supportive care, which can reduce the case-fatality rate in hospitalized patients from approximately 10% to less than 0.5% (1, 9). The clinical management of patients depends on recognition of the 3 phases of dengue: the febrile phase, critical phase, and recovery phase. During the febrile phase, maintaining proper hydration and vigilance for the warning signs of severe dengue are important. Defervescence, typically 3–7 days after illness onset, defines the start of the critical phase, which typically lasts 24–48 hours. Hemoconcentration may also occur as a result of plasma leakage in the critical phase, in which case judicious use of intravenous fluids and close monitoring of clinical status are needed to avert shock, organ impairment, and unnecessary morbidity. Corticosteroids, though once thought to benefit dengue patients, have not been shown to decrease mortality or morbidity due to dengue and in fact may result in increased morbidity due to immunosuppression and/ or the increased risk of gastrointestinal bleeding (10, 11). The recovery phase reflects a return to normal capillary permeability, although continued monitoring of fluid status is important to avoid fluid overload. Detailed patient management protocols and best practice guidelines elaborate on the appropriate clinical management of patients suspected of having or with confirmed dengue (Figure 1) (1).

## Dengue epidemiology

Outbreaks of dengue-like illnesses were first reported in the 1600s and have been consistently reported from various regions of the tropics for more than a century. Although the Americas experienced a reprieve from dengue in the 1950s and 1960s following an

extensive *Aedes aegypti* elimination program by the Pan American Health Organization (PAHO) (12), the recent resurgence of dengue in the region reflects global trends (1, 13, 14) in urbanization and migration and demonstrates that current prevention measures are inadequate (15,16). The number of dengue cases reported to WHO nearly doubled between the 1990s and the early 2000s (17), and in 2010 an estimated 96 million dengue cases occurred worldwide (2). The need to evaluate the economic impact of dengue and novel prevention methods, such as vaccines, underscores the importance of maintaining disease surveillance to better understand changes in dengue epidemiology.

The seasonal and cyclical natures of dengue are due in part to environmental influences, in particular rainfall, temperature (18), and weather indices such as El Niño Southern Oscillation (19), all of which affect the proportion of individuals in the population that are susceptible to the DENV types in circulation. DENV transmission via the vector *Ae. aegypti* tends to increase as conditions favor the reproduction of mosquitos. Nevertheless, a recent review of the literature emphasizes the complex interactions between environment, the mosquito vector, and host factors in the propagation of DENV, cautioning that the current methods, which rely on environmental models to predict the spread of dengue, have limitations (20).

## Dengue in Puerto Rico

The first reported dengue outbreak in Latin America occurred in the early 1600s on the Caribbean island of Martinique (21). Similar outbreaks of a dengue-like illness spread throughout Latin America over the subsequent 3 centuries (21). In Puerto Rico, outbreaks of a dengue-like illness were reported in 1918 (22) and in 1945 (23), DENV-2 was isolated during an outbreak in 1963–1964 and endemicity of dengue was documented soon after (24). The introduction of additional DENV types was documented in outbreaks in the 1970s and 1980s, and in 1998 an outbreak occurred in which all 4 DENV types were circulating (25). Dengue epidemics occurred most recently in Puerto Rico in 2007 (26), 2010 (27), and 2012–2013 (PRDH, unpublished data) (Figure 2).

Dengue epidemiology in Puerto Rico during epidemic and non-epidemic years consistently reveals a disproportionate burden of disease for individuals aged 10–19 years, followed by younger children and infants; nonetheless, adults consistently represent roughly one-half of all reported cases (25–27). There have been no consistent differences in the incidence of dengue by sex or race. In 2007, a total of 10,508 suspected cases and 44 deaths were reported; however, only one-third of the suspected cases and 11 of the fatal cases had laboratory evidence of DENV infection. Moreover, among all the laboratory-positive dengue cases identified, the percentage of individuals that had been previously infected with a DENV was greater than 75% (26). A separate investigation regarding the 11 lab-confirmed deaths revealed that less than half received a clinical diagnosis of dengue, more than half were given corticosteroids, and none were managed according to the WHO guidelines (28). Subsequently, the 2010 epidemic documented nearly 27,000 suspected cases and 128 fatal cases, of which half and one-third were laboratory confirmed, respectively (27). Similar to the 2007 epidemic, approximately 80% of the dengue cases had been previously infected with a DENV. The 2007 and 2010 epidemics illustrated critical lessons about dengue

epidemiology in Puerto Rico and revealed several aspects of dengue clinical case management in need of improvement (e.g., use of non-isotonic intravenous saline, frequency of vital sign monitoring, administration of corticosteroids).

## Dengue surveillance in Puerto Rico

Dengue in Puerto Rico is monitored with the Passive Dengue Surveillance System (PDSS), which was established in the late 1960s (29). PDSS was, for several decades, a collaborative surveillance system co-operated by Puerto Rico Department of Health (PRDH) and the Centers for Disease Control and Prevention-Dengue Branch (CDC-DB) located in San Juan. However, since 2012, the PDSS has been operated primarily by PRDH. A general overview of PDSS spans from the initial interfacing of a patient with the health care system to the reporting of a suspected dengue case to the public health response (Figure 3). Overall goals of dengue surveillance<sup>1</sup> include the early detection of increased incidence to enable early intervention, measurement of disease burden, evaluation of programs to prevent and control dengue, and facilitation of appropriate resource distribution.

An evaluation of PDSS from 2009–2011, guided by the 9 attributes of public health surveillance (30), identified strength in the utility, flexibility, and stability of the system; however, timeliness, sensitivity, and acceptability represented attributes to be improved (CDC-DB, unpublished data). Data quality, positive predictive value, and simplicity of the surveillance system were considered to be acceptable. The total times for specimens to be transported (Figure 4), processed, tested, and reported back to clinicians were 10 days in an epidemic period and 15 days during a non-epidemic period, thus reducing the clinical utility of diagnostic testing for health care providers. Nevertheless, the primary purpose of PDSS is to inform public health decision-making and not to produce diagnostic test results. The stability of PDSS over the past several decades contributes to its utility in monitoring dengue epidemiology and in directing public health action in Puerto Rico.

An inherent limitation of passive surveillance is the difficulty of measuring the true burden of disease. A meta-analysis of surveillance systems throughout Latin America and Southeast Asia revealed significant underreporting of dengue cases: from 3–9 symptomatic cases not being reported for each case that was reported (31). Studies in Puerto Rico in the 1990s estimated that for each case of dengue reported to the PDSS, 10–27 additional cases were not reported (32, 33). Although recent estimates of underreporting are needed, much anecdotal evidence suggests that PDSS is biased towards hospitalized cases (CDC-DB, unpublished data).

To improve surveillance, a pilot enhanced surveillance system was implemented in 2005 in Patillas to encourage health care providers to report suspected cases (34). In 2009, the WHO recommended the addition of sentinel surveillance systems to complement passive surveillance (1, 31). To meet this need, in 2012 CDC-DB established the Sentinel Enhanced Dengue Surveillance System (SEDSS) in Ponce, and later expanded it to sites in Guayama and Carolina (35). A major utility of the SEDSS sites includes the ability to determine baseline levels of dengue, which will be needed to evaluate the efficacy of a dengue vaccine and more accurately quantitate the burden of all clinically-apparent dengue cases. This will

enable a better understanding and evaluation of interventions that are implemented to control dengue in Puerto Rico.

## Dengue diagnosis

Dengue surveillance systems in Puerto Rico, both passive and enhanced, depend on accurate diagnostic testing to identify DENV-infected individuals; however, the time between specimen collection and laboratory confirmation frequently approaches 2 or more weeks due primarily to delays in specimen transport and in the subsequent receipt of reports containing diagnostic test results (CDC-DB, unpublished data). Consequently, surveillance-based diagnostic testing provides minimal clinical utility to the health care provider. Rapid diagnostic tests, in conjunction with a clinical diagnosis of probable dengue, promise greater utility in population-based surveillance for dengue, particularly in resource-poor settings in which instrument-independent laboratory diagnostics are necessary (36, 37). Despite this, rapid diagnostic tests have not yet been demonstrated to be sufficiently reliable to enable individual patient diagnosis and management. Alternatively, highly sensitive and specific laboratory-based diagnostic tests are now available that can accurately diagnose dengue patients using a single serum specimen. Both molecular (38) and serologic (39) diagnostic tests that have been approved by the FDA are available in Puerto Rico at PRDH and CDC-DB, and currently all submitted specimens are tested for evidence of DENV infection. However, until these or other tests are available at centralized locations in hospitals and clinics, the clinical diagnosis made by the health care provider will continue to be the primary method used to diagnose and, consequently, treat suspected dengue cases.

The clinical diagnosis of dengue in endemic areas is often complicated by the myriad of other endemic acute febrile illnesses (AFIs) and the dynamic epidemiologic trends of such diseases. Influenza, leptospirosis, an array of respiratory illnesses, and various other bacterial infections often muddle the picture of a non-differentiated AFI, which may be misdiagnosed as dengue during dengue epidemics (40). The aforementioned WHO criteria for dengue demonstrate considerable overlap of the non-specific symptoms with those of other AFIs. Furthermore, the recent emergence of chikungunya in Puerto Rico (41), which has a clinical presentation similar to that of dengue and is also transmitted by *Aedes* species mosquitoes (42), further complicates the identification of dengue patients.

Historically, epidemiologic studies focus primarily on differentiating laboratory-positive dengue patients from dengue-negative patients in regions with endemic dengue. One systematic review (43) and studies in Puerto Rico (44) observed associations between dengue cases and decreased platelets and white blood cell count in addition to observing an increased proportion of patients with myalgia, rash, and hemorrhagic signs. Specific comparisons between patients with dengue or influenza revealed high proportions of rash, hemorrhagic signs, and positive tourniquet test, as well as pronounced thrombocytopenia and leukopenia, among dengue patients (45). The scientific literature regarding the clinical manifestations of dengue, though varied in the development of predictive models and likely influenced by the circulation of different DENV types, provides a framework from which to evaluate the utility of clinical diagnoses and improve the timeliness of diagnosis.

## Advances in dengue prevention

In 2003, the Pan American Health Organization (PAHO) developed the Integrated Management Strategy for Dengue Prevention and Control (*Patio Limpio*), and most countries in the region adopted this approach; however, the impact of this program has since been shown to be minimal (21). The lack of effective approaches in terms of the primary prevention of dengue (e.g., a dengue vaccine, sustainable and effective vector control methods) therefore demonstrates the importance of secondary prevention (e.g., disease surveillance, clinical diagnosis, patient management) in mitigating the morbidity and mortality associated with dengue.

An example of this is that after noting the sub-optimal management of fatal dengue cases during the 2007 epidemic in Puerto Rico (46), medical epidemiologists from CDC-DB utilized the 2009 WHO Dengue Guidelines (1) to design a 4-hour clinical training course for physicians, that outlined the recommended management of dengue patients. When the 2010 epidemic was growing in magnitude and fatal cases began to be reported, the Secretary of Health of Puerto Rico mandated that all clinicians who see dengue patients take the course, and more than 11,000 clinicians were ultimately trained. An evaluation of clinical practices in 2009 compared to 2011 demonstrated significant increases in adherence to the recommended clinical practices, such as the use of isotonic intravenous saline, frequency of monitoring vital signs, and avoidance of corticosteroid administration (CDC-DB, unpublished data). This course was subsequently developed into an online training (available at [www.cdc.gov/dengue/training/cme.html](http://www.cdc.gov/dengue/training/cme.html)) that clinicians can take to receive continuing medical education credit. Thus, although an effective and sustainable approach to the primary prevention of dengue is not yet available, improvements in the clinical management of hospitalized dengue patients can reduce the case-fatality rate to below 0.5% (9).

Despite the recognition of dengue as a neglected tropical disease, considerable attention by global, regional, and local stakeholders has produced invaluable resources to guide preventive efforts. The most recent initiative by the WHO focuses on diagnosis and case management, integrated surveillance and outbreak preparedness, sustainable vector control, future vaccine implementation, and basic operational and implementation research as key components to reduce dengue mortality by 50% and morbidity by 25% by 2020 (47).

Recent advances in dengue vaccine development offer hope for control and prevention. One vaccine candidate reported an overall efficacy of 56%, with an excellent safety profile from a phase III trial in Southeast Asia (48), though sub-optimal protection against illness due to infection with DENV-2 was consistent with previous studies (8). Nevertheless, the potential to prevent dengue, especially severe cases (49), with this vaccine and others (50) in development underscores the importance of accurate clinical diagnosis and surveillance to measure the impact of those vaccines. Therefore, until a vaccine or other sustainable and effective approach to dengue control becomes available, health professionals will continue to play the most critical role in the clinical management of individuals with dengue or other AFI in Puerto Rico.



## Acknowledgments

This publication was supported by the Centers for Disease Control and Prevention (CDC) and the Oregon Clinical and Translational Research Institute (OCTRI) under grant number TL1TR000129 from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH).


## References

1. World Health Organization. Dengue : Guidelines for diagnosis, treatment, prevention, and control. Geneva, Switzerland: World Health Organization; 2009. Special Programme for Research and Training in Tropical Diseases.
2. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. *Nature*. 2013; 496:504–507. [PubMed: 23563266]
3. Deen JL, Harris E, Wills B, et al. The WHO dengue classification and case definitions: Time for a reassessment. *Lancet*. 2006; 368:170–173. [PubMed: 16829301]
4. Bandyopadhyay S, Lum LCS, Kroeger A. Classifying dengue: A review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. *Trop Med Int Health*. 2006; 11:1238–1255. [PubMed: 16903887]
5. Barniol J, Gaczowski R, Barbato EV, et al. Usefulness and applicability of the revised dengue case classification by disease: Multi-centre study in 18 countries. *BMC Infect Dis*. 2011; 11:106. [PubMed: 21510901]
6. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: An historical perspective and role of antibody-dependent enhancement of infection. *Arch Virol*. 2013; 158:1445–1459. [PubMed: 23471635]
7. Wallace D, Canouet V, Garbes P, Wartel TA. Challenges in the clinical development of a dengue vaccine. *Curr Opin Virol*. 2013; 3:352–356. [PubMed: 23747120]
8. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in thai schoolchildren: A randomised, controlled phase 2b trial. *Lancet*. 2012; 380:1559–1567. [PubMed: 22975340]
9. Lam PK, Tam DTH, Diet TV, et al. Clinical characteristics of dengue shock syndrome in vietnamese children: A 10-year prospective study in a single hospital. *Clin Infect Dis*. 2013; 57:1577–1586. [PubMed: 24046311]
10. Rajapakse S, Rodrigo C, Maduranga S, Rajapakse AC. Corticosteroids in the treatment of dengue shock syndrome. *Infect Drug Resist*. 2014; 7:137–143. [PubMed: 24899817]
11. Menon K, McNally D, Choong K, Sampson M. A systematic review and meta-analysis on the effect of steroids in pediatric shock. *Pediatr Crit Care Med*. 2013; 14:474–480. [PubMed: 23867428]
12. Tapia-Conyer R, Méndez-Galván JF, Gallardo-Rincón H. The growing burden of dengue in Latin America. *J Clin Virol*. 2009; 46(Suppl 2):S3–S6. [PubMed: 19800563]
13. Murray NEA, Quam MB, Wilder-Smith A. Epidemiology of dengue: Past, present and future prospects. *Clin Epidemiol*. 2013; 5:299–309. [PubMed: 23990732]
14. Gubler DJ. Dengue, urbanization and globalization: The unholy trinity of the 21st century. *Trop Med Health*. 2011; 39(4 Suppl):3–11. [PubMed: 22500131]
15. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. *Trends Micro-biol*. 2002; 10:100–103.
16. Herrera-Martinez AD, Rodríguez-Morales AJ. Potential influence of climate variability on dengue incidence registered in a western pediatric hospital of Venezuela. *Trop Biomed*. 2010; 27:280–286. [PubMed: 20962726]
17. Guzman MG, Halstead SB, Artsob H, et al. Dengue: A continuing global threat. *Nat Rev Microbiol*. 2010; 8(12 Suppl):S7–16. [PubMed: 21079655]
18. Jury MR. Climate influence on dengue epidemics in Puerto Rico. *Int J Environ Health Res*. 2008; 18(5):323–334. [PubMed: 18821372]


19. Johansson M, Cummings D, Glass G. Multiyear climate variability and dengue-El niño southern oscillation, weather, and dengue incidence in Puerto Rico, Mexico, and Thailand: A longitudinal data analysis. *PLoS Med.* 2009; 6:e1000168. [PubMed: 19918363]
20. Morin CW, Comrie AC, Ernst K. Climate and dengue transmission: Evidence and implications. *Environ Health Perspect.* 2013; 121:1264–1272. [PubMed: 24058050]
21. Brathwaite Dick O, San Martín JL, Montoya RH, et al. The history of dengue outbreaks in the Americas. *Am J Trop Med Hyg.* 2012; 87:584–593. [PubMed: 23042846]
22. King W. The epidemic of dengue in Porto Rico:1915. *New Orleans Med Surg J.* 1917; 69:564–571.
23. Diaz-Rivera R. A bizarre type of seven day fever clinically indistinguishable from dengue. *Bol Asoc Med P R.* 1946; 38:75–80. [PubMed: 20984756]
24. Ehrenkranz NJ, Ventura AK, Cuadrado RR, et al. Pandemic dengue in Caribbean countries and the southern United States--past, present and potential problems. *N Engl J Med.* 1971; 285:1460–1469. [PubMed: 4941592]
25. Rigau-Pérez JG, Ayala-López A, García-Rivera EJ, et al. The reappearance of dengue-3 and a subsequent dengue-4 and dengue-1 epidemic in Puerto Rico in 1998. *Am J Trop Med Hyg.* 2002; 67:355–362. [PubMed: 12452489]
26. Tomashek K, Rivera A, Muñoz-Jordan J, et al. Description of a large island-wide outbreak of dengue in Puerto Rico, 2007. *Am J Trop Med Hyg.* 2009; 81:467–474. [PubMed: 19706917]
27. Sharp TM, Hunsperger E, Santiago GA, et al. Virus-specific differences in rates of disease during the 2010 dengue epidemic in Puerto Rico. *PLoS Negl Trop Dis.* 2013; 7:e2159. [PubMed: 23593526]
28. Tomashek KM, Gregory CJ, Rivera Sánchez A, et al. Dengue deaths in Puerto Rico: Lessons learned from the 2007 epidemic. *PLoS Negl Trop Dis.* 2012; 6:e1614. [PubMed: 22530072]
29. Likosky WH, Calisher CH, Michelson AL. An epidemiologic study of dengue type 2 in Puerto Rico, 1969. *Am J Epidemiol.* 1973; 97:264–275. [PubMed: 4697647]
30. German RR, Lee LM, Horan JM, et al. Guidelines Working Group Centers for Disease Control and Prevention (CDC). Updated guidelines for evaluating public health surveillance systems: recommendations from the Guidelines Working Group. *MMWR Recomm Rep.* 2001; 50:1–35. [PubMed: 18634202]
31. Runge-Ranzinger S, Horstick O, Marx M, Kroeger A. What does dengue disease surveillance contribute to predicting and detecting outbreaks and describing trends? *Trop Med Int Health.* 2008; 13:1022–1041. [PubMed: 18768080]
32. Rigau-Pérez JG. Surveillance for an emerging disease: Dengue hemorrhagic fever in Puerto Rico, 1988–1997. *Puerto Rico Association of Epi-demiologists. P R Health Sci J.* 1999; 18:337–345. [PubMed: 10730300]
33. Dechant EJ, Rigau-Pérez JG. Hospitalizations for suspected dengue in Puerto Rico, 1991–1995: Estimation by capture-recapture methods. *Am J Trop Med Hyg.* 1999; 61:574–578. [PubMed: 10548291]
34. Ramos MM, Argüello DF, Luxemburger C, et al. Epidemiological and clinical observations on patients with dengue in Puerto Rico: Results from the first year of enhanced surveillance - June 2005–May 2006. *Am J Trop Med Hyg.* 2008; 79:123–127. [PubMed: 18606775]
35. Tomashek K, Lorenzi-Peña O, Margolis H. Sentinel enhanced dengue surveillance in Puerto Rico: A proposal for establishment of the first sentinel site in the Ponce health region. 2011
36. Andries A-C, Duong V, Ngan C, et al. Field evaluation and impact on clinical management of a rapid diagnostic kit that detects dengue NS1, IgM and IgG. *PLoS Negl Trop Dis.* 2012; 6:e1993. [PubMed: 23301110]
37. Gan VC, Tan L-K, Lye DC, et al. Diagnosing dengue at the point-of-care: Utility of a rapid combined diagnostic kit in Singapore. *PLoS ONE.* 2014; 9:90037.
38. Santiago GA, Vergne E, Quiles Y, et al. Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus. *PLoS Negl Trop Dis.* 2013; 7:2311.
39. Namekar M, Ellis EM, O'Connell M, et al. Evaluation of a new commercially available immunoglobulin M capture enzyme-linked immuno-sorbent assay for diagnosis of dengue virus infection. *J Clin Microbiol.* 2013; 51:3102–3106. [PubMed: 23824771]




40. Bruce MG, Sanders EJ, Leake JAD, et al. Leptospirosis among patients presenting with dengue-like illness in Puerto Rico. *Acta Trop*. 2005; 96:36–46. [PubMed: 16083836]
41. Sharp TM, Roth NM, Torres J, et al. Chikungunya cases identified through passive surveillance and household investigations –Puerto Rico, May 5–August 12, 2014. *MMWR Morb Mortal Wkly Rep*. 2014; 63:1121–1128. [PubMed: 25474032]
42. Malvy D, Ezzedine K, Mamani-Matsuda M, et al. Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. *BMC Infect Dis*. 2009; 9:200. [PubMed: 20003320]
43. Potts JA, Rothman AL. Clinical and laboratory features that distinguish dengue from other febrile illnesses in endemic populations. *Trop Med Int Health*. 2008; 13:1328–1340. [PubMed: 18803612]
44. Gregory CJ, Santiago LM, Argüello DF, et al. Clinical and laboratory features that differentiate dengue from other febrile illnesses in an endemic area--Puerto Rico, 2007–2008. *Am J Trop Med Hyg*. 2010; 82:922–929. [PubMed: 20439977]
45. Lorenzi OD, Gregory CJ, Santiago LM, et al. Acute febrile illness surveillance in a tertiary hospital emergency department: Comparison of influenza and dengue virus infections. *Am J Trop Med Hyg*. 2013; 88:472–480. [PubMed: 23382160]
46. Tomashek KM, Gregory CJ, Rivera Sánchez A, et al. Dengue deaths in Puerto Rico: Lessons learned from the 2007 epidemic. *PLoS Negl Trop Dis*. 2012; 6:1614.
47. World Health Organization. WHO global strategy for dengue prevention and control, 2012–2020. Geneva, Switzerland: 2012.
48. Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial. *Lancet*. 2014; 384:1358–1365. [PubMed: 25018116]
49. Wilder-Smith A. Dengue vaccines: Dawning at last? *Lancet*. 2014; 384:1327–1329. [PubMed: 25018119]
50. Norrby R. Outlook for a dengue vaccine. *Clin Microbiol Infect*. 2014; 20(Suppl 5):92–94. [PubMed: 24438016]



**Figure 1.** Schematic of World Health Organization guidelines (1) for clinical management of patients suspected of having dengue.




**Figure 2.** Suspected dengue cases reported to the passive dengue surveillance system during 1986–2013. The dotted horizontal line indicates the epidemic threshold.

**Figure 3.**

Schematic of how the passive dengue surveillance system (PDSS) operated until 2012.

PDSS is initiated when a patient seeks medical care, following which the patient's medical provider suspects dengue as a cause of the patient's illness. When this occurs, the clinician orders a blood specimen be collected from the patient and the Dengue Case Investigation Form (DCIF) is completed; both the specimen and DCIF are transported by the Puerto Rico Department of Health (PRDH) to the Centers for Disease Control and Prevention, Dengue Branch (CDC-DB). Specimens are tested, and the patient information from the DCIF is entered into a database at the CDC-DB. Diagnostic test results are sent to the health care provider who reported the case, who then relays the results to the patient and, if necessary, requests that the patient return to provide a convalescent serum specimen. Patient demographic information is compiled into weekly reports that CDC-DB and PRDH disseminate to stakeholders and the public via weekly reports. PRDH uses data from these reports to direct response activities in the areas most affected by dengue. After 2012, all activities indicated as being conducted by CDC-DB began instead to be conducted by PRDH.



**Figure 4.** Median number of days needed for a specimen to arrive at Centers for Disease Control and Prevention, Dengue Branch (CDC-DB), according to a particular patient's municipality of residence in 2009 (A), 2010 (B) and 2011 (C). Light green, dark green, yellow, and red regions indicate municipalities with an average transport time of 0–2, 3–4, 5–7, and >8 days, respectively.